Great Basin Expands Product Development Leadership
27 April 2016 - 10:00PM
Business Wire
Suzette Chance, Ph.D., tapped to serve as
senior director of clinical affairs
Great Basin Scientific, Inc. (NASDAQ:GBSN), a molecular
diagnostics company, has appointed Suzette Chance, Ph.D. to serve
as senior director of clinical affairs. In her role, Dr. Chance
will lead clinical trial strategy and execution for Great Basin’s
diagnostic products, beginning with upcoming trials for: Candida
Blood Infections Panel; SA Nasal Screen Test; CT/NG Test; Stool
Bacterial Pathogens Panel; and Pertussis/Parapertussis Test. All
five trials are slated to begin in 2016 with expected clearance
timeframes throughout 2017.
Dr. Chance has more than 20 years of experience in the in vitro
diagnostics industry, and has a proven record of success taking
product ideas from concept through commercialization, including
clinical trials and U.S. Food & Drug Administration (FDA)
clearance. Most recently, Dr. Chance served as senior director of
research and development at Immucor GTI Diagnostics in Waukesha,
Wis., where she specialized in transplantation and transfusion
medicine. Prior to that, she served in R&D roles with
Gen-Prob/Hologic and Genetic Testing Institute. Dr. Chance began
her career as a scientist and biochemist with DuPont Medical
Products in Glasgow, Del., where she created and established a new
bio-analytical laboratory for the DuPont facility. She earned her
B.S. degree in biochemistry at the University of Minnesota, her
Ph.D. in biochemistry at Johns Hopkins University; School of
Hygiene and Public Health, and completed a post-doctoral fellowship
at Johns Hopkins University, School of Medicine, Department of Cell
Biology and Anatomy. Dr. Chance has successfully shepherded more
than 22 new products through the development and regulatory process
in her career.
“Great Basin is committed to a very aggressive schedule for
delivering new tests and panels that meet the needs of our current
customers and spur adoption of Great Basin’s easy-to-use and
cost-effective solution in new hospitals and labs,” said Robert D.
Jenison, chief technology officer, Great Basin Scientific.
“Suzette’s experience and leadership will be key to our ability to
successfully deliver on our menu goals of nine cleared assays in
2017, and 16 to 17 assays in 2018. We are thrilled to welcome
someone as knowledgeable and successful as Suzette to help us
refine and expedite our clinical trial and FDA 510(K) submission
processes as we embark on this exciting time of growth.”
About Great Basin Scientific
Great Basin Scientific is a molecular diagnostics company that
commercializes breakthrough chip-based technologies. The Company is
dedicated to the development of simple, yet powerful,
sample-to-result technology and products that provide fast,
multiple-pathogen diagnoses of infectious diseases. The Company’s
vision is to make molecular diagnostic testing so simple and
cost-effective that every patient will be tested for every serious
infection, reducing misdiagnoses and significantly limiting the
spread of infectious disease. More information can be found on the
company’s website at www.gbscience.com.
Forward-Looking Statements
This press release includes forward-looking statements regarding
the Company’s continuing business efforts related to its products,
including but not limited to planned tests to be brought to
clinical trial in 2016, target customer group and related
statements. Forward-looking statements involve risk and
uncertainties, which could cause actual results to differ
materially, and reported results should not be considered as an
indication of future performance. These risk and uncertainties
include, but are not limited to: (i) our limited operating history
and history of losses; (ii) our ability to develop and
commercialize new products and the timing of commercialization;
(iii) our ability to obtain capital when needed; and (iv) other
risks set forth in the Company’s filings with the Securities and
Exchange Commission, including the risks set forth in the company’s
Annual Report on Form 10-K for the fiscal year ended December 31,
2015. These forward-looking statements speak only as of the date
hereof and Great Basin Scientific specifically disclaims any
obligation to update these forward-looking statements, except as
required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160427005351/en/
Media:ICRKate Ottavio Kent,
203-682-8276Kate.Ottavio-Kent@icrinc.comorInvestor
Relations:CorProminenceScott Gordon,
516-222-2560gbinfo@corprominence.comorICRDavid Clair,
646-277-1266David.Clair@icrinc.com